Bank of New York Mellon Corp boosted its position in Cerus Corporation (NASDAQ:CERS) by 1.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 505,652 shares of the biotechnology company’s stock after buying an additional 6,710 shares during the period. Bank of New York Mellon Corp’s holdings in Cerus Corporation were worth $2,250,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of CERS. Norges Bank purchased a new stake in Cerus Corporation during the fourth quarter worth approximately $3,407,000. First Midwest Bank Trust Division increased its stake in Cerus Corporation by 188.6% in the first quarter. First Midwest Bank Trust Division now owns 644,472 shares of the biotechnology company’s stock worth $2,868,000 after buying an additional 421,164 shares in the last quarter. Peregrine Capital Management LLC increased its stake in Cerus Corporation by 7.3% in the first quarter. Peregrine Capital Management LLC now owns 3,587,940 shares of the biotechnology company’s stock worth $15,715,000 after buying an additional 243,854 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Cerus Corporation during the fourth quarter worth approximately $357,000. Finally, Wells Fargo & Company MN increased its stake in Cerus Corporation by 1.8% in the first quarter. Wells Fargo & Company MN now owns 3,222,458 shares of the biotechnology company’s stock worth $14,339,000 after buying an additional 57,854 shares in the last quarter. Institutional investors own 65.30% of the company’s stock.
Cerus Corporation (CERS) opened at 2.26 on Wednesday. The company’s market cap is $234.90 million. The stock’s 50 day moving average price is $2.38 and its 200-day moving average price is $3.60. Cerus Corporation has a 1-year low of $1.93 and a 1-year high of $7.64.
Cerus Corporation (NASDAQ:CERS) last released its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. The firm had revenue of $7.01 million for the quarter, compared to analysts’ expectations of $8.98 million. Cerus Corporation had a negative net margin of 168.39% and a negative return on equity of 104.79%. On average, analysts forecast that Cerus Corporation will post ($0.62) earnings per share for the current year.
A number of equities research analysts have issued reports on the company. Cantor Fitzgerald set a $9.00 price objective on Cerus Corporation and gave the company a “buy” rating in a research report on Thursday, May 4th. Cowen and Company decreased their price objective on Cerus Corporation from $9.50 to $7.00 and set an “outperform” rating on the stock in a research report on Monday, April 17th. ValuEngine downgraded Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 17th. Zacks Investment Research downgraded Cerus Corporation from a “hold” rating to a “sell” rating in a research report on Friday, May 26th. Finally, BTIG Research restated a “buy” rating and set a $5.00 price objective on shares of Cerus Corporation in a research report on Sunday, May 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $7.80.
About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Corporation (NASDAQ:CERS).
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
